BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially around China, the analyst tells investors in a preview for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics launches AD-Detect blood test for Alzheimer’s confirmation
- Quest Diagnostics price target raised to $189 from $178 at Mizuho
- Quest Diagnostics initiated with a Buy at Redburn Atlantic
- Quest Diagnostics: Steady Growth and Strategic Advancements Justify Buy Rating
- Quest Diagnostics: Resilient Investment with Strategic Growth Initiatives and Strong Financials